Okay, toh baat yeh hai ki Novo Nordisk apni blockbuster drugs Ozempic aur Wegovy ko India mein aam logon ke liye zyada accessible banane ki koshish kar raha hai. Isliye, woh prices ko 48% tak girane wale hain, April 2026 se. Ozempic ka starting dose 36% sasta ho jayega aur Wegovy ka starting dose 48% kam. Weekly cost around ₹1,415 ho jayega.
Aakhir yeh sab kyun ho raha hai? (The Real Reason!)
Asal game patent expiry ka hai. Novo Nordisk ka patent March 20, 2026 ko khatam ho raha hai, aur India ke lagbhag 40 local companies iske baad semaglutide ke saste generics launch karne wali hain. Yeh generics original se 60-70% tak kam price par milenge, kuch toh ₹1,290 per month mein bhi aa jayenge. Is competition ko dekh kar hi Novo Nordisk apna price tag ₹8,800-₹16,400 range se niche la raha hai. Global level par in drugs ne $30 billion se zyada kamaya hai 2024 mein, toh India market bhi important hai unke liye.
Competitors Ready Hain!
Sun Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences, aur Torrent Pharmaceuticals jaise bade players already apne semaglutide versions lekar aa rahe hain. Delhi High Court mein Dr. Reddy's ke 'Olymviq' brand par bhi ek case chala kyunki uska naam Ozempic jaisa lag raha tha. Yeh dikhata hai ki branding par bhi ab scrutiny badh rahi hai. Indian market mein in drugs ka business 2024 mein $110.55 million ka tha aur yeh badhne wala hai.
Investors Ka Kya Scene Hai?
Is competition aur price cut se Novo Nordisk ke profits par bhi pressure aa raha hai. Company ka P/E ratio ab 9.94 hai, jo uske 5-year average se kaafi kam hai. Investors ko lagta hai ki future growth aur profit margins ko lekar kuch risks hain. Goldman Sachs ne bhi March mein rating down kar di thi aur $41 ka target diya tha, jo market ki caution dikhata hai.
Sirf Price Cut Hi Nahi Hai...
Novo Nordisk sirf price kam nahi kar raha, balki strategy bhi badha raha hai. Unhone Emcure Pharmaceuticals ke saath partnership ki hai Wegovy ka dusra brand, Poviztra®, distribute karne ke liye. Woh oral anti-obesity drugs bhi laane wale hain. Experts ki rai mili-juli hai, par yeh drugs market $190 million tak pahunch sakta hai 2033 tak.